Top Growth Stocks To Research – January 24th

Prologis, Ascendis Pharma A/S, Teledyne Technologies, Hamilton Lane, and Tyra Biosciences are the five Growth stocks to watch today, according to MarketBeat’s stock screener tool. Growth stocks are shares of companies expected to increase revenue and earnings faster than the overall market, and investors buy them primarily for capital appreciation rather than current income. They typically reinvest profits into expansion, trade at higher valuation multiples (for example, elevated P/E ratios), and can be more volatile and risky than value or dividend-paying stocks. These companies had the highest dollar trading volume of any Growth stocks within the last several days.

Prologis (PLD)

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. At March 31, 2024, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 1.2 billion square feet (115 million square meters) in 19 countries.

Ascendis Pharma A/S (ASND)

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

Teledyne Technologies (TDY)

Teledyne Technologies Incorporated, together with its subsidiaries, provides enabling technologies for industrial growth markets in the United States and internationally. Its Digital Imaging segment provides visible spectrum sensors and digital cameras; and infrared, ultraviolet, visible, and X-ray spectra; as well as micro electromechanical systems and semiconductors, including analog-to-digital and digital-to-analog converters.

Hamilton Lane (HLNE)

Hamilton Lane Incorporated is a private equity firm specializing in early venture, emerging growth, turnaround, middle market, mature, mid-venture, bridge, buyout, distressed/vulture, loan, mezzanine in growth capital companies. It prefers to invest in energy, industrials, consumer discretionary, health care, real estate, information technology, utilities, and consumer services.

Tyra Biosciences (TYRA)

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.